Cognifisense, Inc.
Capital Timeline
Capital this company has received, each line traceable to a primary record. Amounts are obligations, not contract ceilings.
A blank stage means the data is not ingested yet, not that the money stopped there.
Across the lifetime of these contracts, $2.0M has been obligated and $1.2M paid out. $745K has not been disbursed.
Cumulative from contract start through 2026-08-17. The total above covers only the transactions ingested in the tracking window — a different measure.
- National Institutes of Health$01
Why It Matters
Not enough signal yet to assess this company's relevance to Japanese firms.
Events
Events used as evidence for Stage / LCI. Facts and interpretation are recorded separately.
COGNIFISENSE, INC. — Grant R44NR017575
EFFICACY OF A VIRTUAL REALITY NEUROSCIENCE-BASED THERAPY FOR CHRONIC LOW BACK PAIN - PROJECT SUMMARY / ABSTRACT COGNIFISENSE HAS DEVELOPED A UNIQUE, PATENTED VR THERAPY FOR CHRONIC PAIN, CALLED VIRTUAL REALITY NEUROSCIENCE- BASED THERAPY (VRNT). VRNT IS SPECIFICALLY DESIGNED TO CREATE SUBSTANTIAL AND LASTING PAIN REDUCTION BY TARGETING THE CENTRALIZED DRIVERS OF PAIN CHRONIFICATION AND AMPLIFICATION. FOLLOWING OUR HIGHLY SUCCESSFUL PHASE I STUDY, THE GOAL OF THIS PHASE II PROJECT IS TO MAKE THE VRNT SYSTEM MARKET-READY AND DEMONSTRATE ITS EFFICACY IN A PIVOTAL RANDOMIZED CONTROLLED TRIAL (RCT). PHASE II DATA WILL SUBSEQUENTLY BE USED IN AN FDA SUBMISSION. CHRONIC PAIN IS A SERIOUS MEDICAL CONDITION IMPACTING AN ESTIMATED 1 IN 5 AMERICANS. CHRONIC LOWER BACK PAIN (CLBP) IS THE MOST COMMON TYPE OF CHRONIC PAIN, AFFECTING 27 MILLION AMERICANS. CHRONIC PAIN IS A COMPLEX BIOPSYCHOSOCIAL CONDITION WITH A SIGNIFICANT CENTRALIZED (CENTRAL NERVOUS SYSTEM) COMPONENT, WHICH MUST BE ADDRESSED TO Y
Timeline
No timeline articles for this company yet.